Oncopeptides AB (ONCO.ST) released Loss for third quarter of -SEK43.971 million
The company's bottom line totaled -SEK43.971 million, or -SEK0.12 per share. This compares with -SEK60.894 million, or -SEK0.27 per share, last year.
The company's revenue for the period rose 40.7% to SEK28.451 million from SEK20.214 million last year.
Oncopeptides AB earnings at a glance (GAAP) :
-Earnings: -SEK43.971 Mln. vs. -SEK60.894 Mln. last year.-EPS: -SEK0.12 vs. -SEK0.27 last year.-Revenue: SEK28.451 Mln vs. SEK20.214 Mln last year.
For comments and feedback contact: [email protected]
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.